Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk

Karl Staser, Su Jung Park, Steven D. Rhodes, Yi Zeng, Yong Zheng He, Matthew A. Shew, Jeffrey R. Gehlhausen, Donna Cerabona, Keshav Menon, Shi Chen, Zejin Sun, Jin Yuan, David Ingram, Grzegorz Nalepa, Feng Chun Yang, D. Clapp

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Neurofibromatosis type 1 (NF1) predisposes individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferative disease (MPD). In genetically engineered murine models, nullizygosity of Nf1, a tumor suppressor gene that encodes a Ras-GTPase-activating protein, results in hyperactivity of Raf/Mek/Erk in hematopoietic stem and progenitor cells (HSPCs). Activated Erk1/2 phosphorylate kinases and transcription factors with myriad mitogenic roles in diverse cell types. However, genetic studies examining Erk1/2's differential and/or combined control of normal and Nf1-deficient myelopoiesis are lacking. Moreover, prior studies relying on chemical Mek/Erk inhibitors have reached conflicting conclusions in normal and Nf1-deficient mice. Here, we show that while single Erk1 or Erk2 disruption did not grossly compromise myelopoiesis, dual Erk1/2 disruption rapidly ablated granulocyte and monocyte production in vivo, diminished progenitor cell number, and prevented HSPC proliferation in vitro. Genetic disruption of Erk1/2 in the context of Nf1 nullizygosity (Mx1Cre+Nf1flox/floxErk1 -/-Erk2flox/flox) fully protects against the development of MPD. Collectively, we identified a fundamental requirement for Erk1/2 signaling in normal and Nf1-deficient hematopoiesis, elucidating a critical hematopoietic function for Erk1/2 while genetically validating highly selective Mek/Erk inhibitors in a leukemia that is otherwise resistant to traditional therapy.

Original languageEnglish
Pages (from-to)329-334
Number of pages6
JournalJournal of Clinical Investigation
Volume123
Issue number1
DOIs
StatePublished - Jan 2 2013

Fingerprint

Neurofibromin 1
Hematopoiesis
Hematopoietic Stem Cells
Myelopoiesis
Juvenile Myelomonocytic Leukemia
ras GTPase-Activating Proteins
Neurofibromatosis 1
Tumor Suppressor Genes
Granulocytes
Monocytes
Leukemia
Transcription Factors
Phosphotransferases
Stem Cells
Cell Count
Cell Proliferation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk. / Staser, Karl; Park, Su Jung; Rhodes, Steven D.; Zeng, Yi; He, Yong Zheng; Shew, Matthew A.; Gehlhausen, Jeffrey R.; Cerabona, Donna; Menon, Keshav; Chen, Shi; Sun, Zejin; Yuan, Jin; Ingram, David; Nalepa, Grzegorz; Yang, Feng Chun; Clapp, D.

In: Journal of Clinical Investigation, Vol. 123, No. 1, 02.01.2013, p. 329-334.

Research output: Contribution to journalArticle

Staser, K, Park, SJ, Rhodes, SD, Zeng, Y, He, YZ, Shew, MA, Gehlhausen, JR, Cerabona, D, Menon, K, Chen, S, Sun, Z, Yuan, J, Ingram, D, Nalepa, G, Yang, FC & Clapp, D 2013, 'Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk', Journal of Clinical Investigation, vol. 123, no. 1, pp. 329-334. https://doi.org/10.1172/JCI66167
Staser, Karl ; Park, Su Jung ; Rhodes, Steven D. ; Zeng, Yi ; He, Yong Zheng ; Shew, Matthew A. ; Gehlhausen, Jeffrey R. ; Cerabona, Donna ; Menon, Keshav ; Chen, Shi ; Sun, Zejin ; Yuan, Jin ; Ingram, David ; Nalepa, Grzegorz ; Yang, Feng Chun ; Clapp, D. / Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 1. pp. 329-334.
@article{54cb85ca35194888b28898e8aff90594,
title = "Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk",
abstract = "Neurofibromatosis type 1 (NF1) predisposes individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferative disease (MPD). In genetically engineered murine models, nullizygosity of Nf1, a tumor suppressor gene that encodes a Ras-GTPase-activating protein, results in hyperactivity of Raf/Mek/Erk in hematopoietic stem and progenitor cells (HSPCs). Activated Erk1/2 phosphorylate kinases and transcription factors with myriad mitogenic roles in diverse cell types. However, genetic studies examining Erk1/2's differential and/or combined control of normal and Nf1-deficient myelopoiesis are lacking. Moreover, prior studies relying on chemical Mek/Erk inhibitors have reached conflicting conclusions in normal and Nf1-deficient mice. Here, we show that while single Erk1 or Erk2 disruption did not grossly compromise myelopoiesis, dual Erk1/2 disruption rapidly ablated granulocyte and monocyte production in vivo, diminished progenitor cell number, and prevented HSPC proliferation in vitro. Genetic disruption of Erk1/2 in the context of Nf1 nullizygosity (Mx1Cre+Nf1flox/floxErk1 -/-Erk2flox/flox) fully protects against the development of MPD. Collectively, we identified a fundamental requirement for Erk1/2 signaling in normal and Nf1-deficient hematopoiesis, elucidating a critical hematopoietic function for Erk1/2 while genetically validating highly selective Mek/Erk inhibitors in a leukemia that is otherwise resistant to traditional therapy.",
author = "Karl Staser and Park, {Su Jung} and Rhodes, {Steven D.} and Yi Zeng and He, {Yong Zheng} and Shew, {Matthew A.} and Gehlhausen, {Jeffrey R.} and Donna Cerabona and Keshav Menon and Shi Chen and Zejin Sun and Jin Yuan and David Ingram and Grzegorz Nalepa and Yang, {Feng Chun} and D. Clapp",
year = "2013",
month = "1",
day = "2",
doi = "10.1172/JCI66167",
language = "English",
volume = "123",
pages = "329--334",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk

AU - Staser, Karl

AU - Park, Su Jung

AU - Rhodes, Steven D.

AU - Zeng, Yi

AU - He, Yong Zheng

AU - Shew, Matthew A.

AU - Gehlhausen, Jeffrey R.

AU - Cerabona, Donna

AU - Menon, Keshav

AU - Chen, Shi

AU - Sun, Zejin

AU - Yuan, Jin

AU - Ingram, David

AU - Nalepa, Grzegorz

AU - Yang, Feng Chun

AU - Clapp, D.

PY - 2013/1/2

Y1 - 2013/1/2

N2 - Neurofibromatosis type 1 (NF1) predisposes individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferative disease (MPD). In genetically engineered murine models, nullizygosity of Nf1, a tumor suppressor gene that encodes a Ras-GTPase-activating protein, results in hyperactivity of Raf/Mek/Erk in hematopoietic stem and progenitor cells (HSPCs). Activated Erk1/2 phosphorylate kinases and transcription factors with myriad mitogenic roles in diverse cell types. However, genetic studies examining Erk1/2's differential and/or combined control of normal and Nf1-deficient myelopoiesis are lacking. Moreover, prior studies relying on chemical Mek/Erk inhibitors have reached conflicting conclusions in normal and Nf1-deficient mice. Here, we show that while single Erk1 or Erk2 disruption did not grossly compromise myelopoiesis, dual Erk1/2 disruption rapidly ablated granulocyte and monocyte production in vivo, diminished progenitor cell number, and prevented HSPC proliferation in vitro. Genetic disruption of Erk1/2 in the context of Nf1 nullizygosity (Mx1Cre+Nf1flox/floxErk1 -/-Erk2flox/flox) fully protects against the development of MPD. Collectively, we identified a fundamental requirement for Erk1/2 signaling in normal and Nf1-deficient hematopoiesis, elucidating a critical hematopoietic function for Erk1/2 while genetically validating highly selective Mek/Erk inhibitors in a leukemia that is otherwise resistant to traditional therapy.

AB - Neurofibromatosis type 1 (NF1) predisposes individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferative disease (MPD). In genetically engineered murine models, nullizygosity of Nf1, a tumor suppressor gene that encodes a Ras-GTPase-activating protein, results in hyperactivity of Raf/Mek/Erk in hematopoietic stem and progenitor cells (HSPCs). Activated Erk1/2 phosphorylate kinases and transcription factors with myriad mitogenic roles in diverse cell types. However, genetic studies examining Erk1/2's differential and/or combined control of normal and Nf1-deficient myelopoiesis are lacking. Moreover, prior studies relying on chemical Mek/Erk inhibitors have reached conflicting conclusions in normal and Nf1-deficient mice. Here, we show that while single Erk1 or Erk2 disruption did not grossly compromise myelopoiesis, dual Erk1/2 disruption rapidly ablated granulocyte and monocyte production in vivo, diminished progenitor cell number, and prevented HSPC proliferation in vitro. Genetic disruption of Erk1/2 in the context of Nf1 nullizygosity (Mx1Cre+Nf1flox/floxErk1 -/-Erk2flox/flox) fully protects against the development of MPD. Collectively, we identified a fundamental requirement for Erk1/2 signaling in normal and Nf1-deficient hematopoiesis, elucidating a critical hematopoietic function for Erk1/2 while genetically validating highly selective Mek/Erk inhibitors in a leukemia that is otherwise resistant to traditional therapy.

UR - http://www.scopus.com/inward/record.url?scp=84873872323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873872323&partnerID=8YFLogxK

U2 - 10.1172/JCI66167

DO - 10.1172/JCI66167

M3 - Article

C2 - 23221339

AN - SCOPUS:84873872323

VL - 123

SP - 329

EP - 334

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -